A United States pharmacopeia chapter 800-centered process improvement proposal for compounding antineoplastic medications in an academic medical center pharmacy
Keywords:
United States Pharmacopeia chapter 800, pharmacy, antineoplastic, National Institute for Occupational Safety and Health, complianceAbstract
It is well described that handling antineoplastic medications without proper personal and environmental protections leads to malignancy, reproductive toxicity, and organ damage. In December 2019, the United States Pharmacopeia Chapter 800 (USP<800>), which addresses the proper handling of hazardous drugs, will be enforceable for any facility handling these agents. Northwestern Memorial Hospital in Chicago, Illinois has developed a process improvement for the central pharmacy clean room to increase compliance to USP<800> standards. This plan specifically focuses on adjusting the workflow of four antineoplastic agents that are compounded in their central pharmacy clean room.
References
Hazardous drugs—handling in healthcare settings(general information chapter 800). In: The United States pharmacopeia, 39th rev., and the national formulary, 34th ed. Rockville, MD: United States Pharmacopeial Convention; 2016:7721-7739.
United States Department of Human Services. Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings. Washington, DC: National Institute for Occupational Safety and Health, 2004.
United States Department of Human Services. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings. Washington, DC: National Institute for Occupational Safety and Health, 2016.
Wolters Kluwer. Simplifi797. Available at: http://www.pharmacyonesource.com/products/simplifi797/. Accessed May 23, 2018.
Mitomycin. Micromedex Solutions. Truven Health Analytics, Inc. Ann Arbor, MI. Available at: http://www.micromedexsolutions.com. Accessed May 23, 2018.
Mitomycin injection, powder, lyophilized, for solution[package insert]. Canonsburg, PA: Mylan Institutional LLC;2017.
Hydroxyurea. Micromedex Solutions. Truven Health Analytics, Inc. Ann Arbor, MI. Available at: http://www.micromedexsolutions.com. Accessed May 23, 2018.
Hydroxyurea [package insert]. Gurnee, IL: Teva Pharmaceuticals USA, Inc; 2016.
Bacillus of Calmette and Guerin Vaccine, Live. Micromedex Solutions. Truven Health Analytics, Inc. Ann Arbor, MI. Available at: http://www.micromedexsolutions.com. Accessed May 23, 2018.
TICE BCG- bacillus calmette-Guerin powder, for suspension [package insert]. Roseland, NJ: Organon USA Inc; 2016.
Methotrexate Sodium. Micromedex Solutions. Truven Health Analytics, Inc. Ann Arbor, MI. Available at: http://www.micromedexsolutions.com. Accessed May 23,2018.
Methotrexate injection [package insert]. Canonsburg, PA: Mylan Institutional LLC; 2014.
Downloads
Published
Issue
Section
License
Authors who publish with the American Journal of Experimental and Clinical Resaerch (AJECR) agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
